Newmed Energ Pu AI Stock Analysis
Want to see IL:NWMD full AI Analyst Report?
Newmed Energ Pu (NWMD) AI Stock Analysis
Newmed Energ Pu
(TASE:NWMD)
The overall score of 66 reflects a company with strong operational momentum and a much-improved balance sheet, offset by significant concerns over free cash flow generation and a high valuation. The most impactful factor is the positive earnings call, highlighting robust production growth and clear future catalysts from infrastructure and expansion projects. This is balanced by the financial performance, where a sharp decline in free cash flow is a major risk. The stock's technical position is neutral, and its high P/E ratio tempers the otherwise positive outlook.
Newmed Energ Pu (NWMD) vs. iShares MSCI Israel ETF (EIS)
- Market Cap
- ILS 19.80B
- Dividend Yield
- 3.56%
- Average Volume (3M)
- 1.05M
- Price to Earnings (P/E)
- 24.3
- Beta (1Y)
- 1.07
- Revenue Growth
- -18.59%
- EPS Growth
- -52.07%
- Country
- Israel
- Employees
- 24
- Sector
- General
- Sector Strength
- 55
- Industry
- Oil & Gas Exploration & Production
Newmed Energ Pu Business Overview & Revenue Model
Company Description
NewMed Energy - Limited Partnership is an energy firm engaged in the exploration, development, production, and commercialization of petroleum, natural gas, and condensate, primarily operating in Israel and Cyprus. The company holds significant intere...
How the Company Makes Money
Newmed Energy primarily makes money by selling natural gas produced from its upstream interests (typically via partners/operators and joint-venture style arrangements) to customers under gas sales agreements. Revenue is generally driven by (1) its sh...
Newmed Energ Pu Earnings Call Summary
The call presented multiple strong operational and financial improvements: production increased ~35%, revenues rose ~53% and net income ~44%, supported by higher gas prices and completed midstream works. Material infrastructure milestones (third pipeline, Ashdod–Ashkelon looping) and progress on major growth projects (Leviathan expansion on schedule, Aphrodite progressing toward FID) provide clear upside. Offsetting considerations include rising operating costs (+$21M), higher finance expenses (+$26M), net debt of ~$1.4B with an upcoming bond maturity in 2027, and some benefits that are timing‑lagged or accrue to partners rather than immediately to NewMed. Overall, positive momentum and meaningful value catalysts outweigh the noted financial and timing challenges.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management guided that Q2‑2026 results included production of 2.7 Bcm (vs. 2.0 Bcm in Q2‑2025, with ~+0.5 Bcm to Egypt), revenues of $293M (vs. $191M), net profit of ~$117–118M, average gas price $6.5/MMBtu (vs. $5.6), and a $60M dividend; net revenues rose ~$86M (≈$59M from higher production, $25M from higher price, $2.1M condensate) partially offset by ~$21M higher costs and ~$26M higher finance expenses, plus $6.8M other revenues and $7.7M discontinued‑operation income. Liquidity/financial guidance: net debt ≈$1.4B, $550M available bank facilities, ~$95M of bond buybacks to date, next bond maturity June‑2027. Capex/project guidance: third pipeline lifts peak capacity to 15.8 Bcm/year (from ~14.5, +1 Bcm), Ashdod–Ashkelon looping adds ~2 Bcm/year (allocated to Leviathan partners), Leviathan Phase‑1b on track for H2‑2029 with total cost ~$2.4B and ~23% complete and a rig to drill 3 wells by year‑end; FAJR+compression due EOY, Nitzana ahead of Phase‑2, Aphrodite FID targeted H1‑2027, and upcoming seismic surveys including a ~5,000‑node OBN survey.
Newmed Energ Pu Financial Statement Overview
Summary
Financial performance is mixed. Profitability remains healthy with TTM gross margins of 50.1% and net margins of 28.8%, but these are declining from peak levels. The balance sheet is a key strength, with debt-to-equity improving dramatically to 0.83x. However, free cash flow has collapsed by 75.5% to just $54.6M, severely limiting financial flexibility and dragging down the overall score.
Income Statement
72PositiveBalance Sheet
68PositiveCash Flow
55Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 911.10M | 938.07M | 1.14B | 934.60M | 1.14B | 882.50M |
| Gross Profit | 557.80M | 585.08M | 718.10M | 780.70M | 701.70M | 518.10M |
| EBITDA | 727.00M | 760.65M | 874.80M | 782.70M | 872.10M | 657.20M |
| Net Income | 263.30M | 371.29M | 524.60M | 433.60M | 469.70M | 404.90M |
Balance Sheet | ||||||
| Total Assets | 4.05B | 3.97B | 3.99B | 3.85B | 3.94B | 3.85B |
| Cash, Cash Equivalents and Short-Term Investments | 163.80M | 157.53M | 384.50M | 186.70M | 418.30M | 340.85M |
| Total Debt | 1.56B | 1.12B | 1.63B | 1.82B | 2.16B | 2.22B |
| Total Liabilities | 2.17B | 2.08B | 2.21B | 2.33B | 2.65B | 2.91B |
| Stockholders Equity | 1.88B | 1.89B | 1.79B | 1.51B | 1.29B | 938.54M |
Cash Flow | ||||||
| Free Cash Flow | 54.61M | 304.72M | 463.30M | 423.10M | 405.80M | 423.25M |
| Operating Cash Flow | 404.03M | 547.08M | 577.50M | 559.50M | 504.70M | 453.64M |
| Investing Cash Flow | -533.88M | 30.20M | -114.20M | 36.10M | -273.50M | 982.04M |
| Financing Cash Flow | -208.48M | -516.12M | -441.20M | -588.90M | -429.10M | -1.29B |
Newmed Energ Pu Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:NWMD, the sentiment is Positive. The current price of 1777.00 is above the 20-day moving average (MA) of 1644.50, above the 50-day MA of 1639.52, and above the 200-day MA of 1742.54, indicating a bullish trend. The MACD of 18.31 indicates Negative momentum. The RSI at 65.73 is Neutral, neither overbought nor oversold. The STOCH value of 85.29 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IL:NWMD.
Newmed Energ Pu Peers Comparison
Overall Rating
IL:TMRP72Outperform- IL:NWMD66Neutral
IL:DLEKG63Neutral
IL:TOEN62Neutral
IL:NVPT59Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| IL:TMRP | 72Outperform | ILS 2.11B | 15.41 | ― | 15.52% | -15.98% | -22.66% |
| IL:NWMD | 66Neutral | ILS 19.80B | 24.30 | 24.33% | 3.56% | -18.59% | -52.07% |
| IL:DLEKG | 63Neutral | ILS 14.25B | 4.18 | 4.49% | 0.07% | -43.39% | 268.02% |
| IL:TOEN | 62Neutral | ILS 267.21M | 14.35 | ― | 37.37% | -1.64% | 9.82% |
| IL:NVPT | 59Neutral | ILS 14.28B | 14.41 | ― | 3.31% | 920.97% | ― |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IL:NWMD | Newmed Energy Limited Partnership | 1777.00 | 114.58 | 6.89% | |
| IL:DLEKG | Delek Group | 7969.00 | -709.17 | -8.17% | |
| IL:ISRA | Isramco Negev 2 LP | 220.90 | -18.18 | -7.61% | |
| IL:TOEN | Tomer Energy Royalties (2012) Ltd. | 1341.00 | -580.47 | -30.21% | |
| IL:TMRP | Tamar Petroleum Ltd. | 2626.00 | -1157.89 | -30.60% | |
| IL:NVPT | Navitas Petroleum LP | 11890.00 | -38.17 | -0.32% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 20, 2026